Pre-clinical melanoma models showed that tumors do not always respond to an anti-CTLA-4 mAb alone, while additive treatments with GM-CSF (121) or activation of the T-cell co-stimulatory receptor 4-1BB (122) are able to promote an anti-tumor response. The gene discussed is CTLA4; the disease is neoplasm.